Work

A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.2014

Authors: M. P. Goetz, S. Safgren, R. M. Goldberg, A. F. Grothey, S. J. Mandrekar, J. M. Reid, C. Erlichman, A. A. Adjei, J. Rubin, M. M. Ames

Institutions: University of North Carolina at Chapel Hill, Mayo Clinic

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589344477

Cites:

Cited by: 4

Related to: 10